Olanzapine versus risperidone in newly admitted acutely ill psychotic patients

Journal of Clinical Psychiatry

Volumn 66, Issue 12, 2005, Pages 1564-1568

  Kraus, John E ^a,b   Sheitman, Brian B ^a,b   Cook, Alan ^a,b   Reviere, Robert ^c   Lieberman, Jeffrey A ^b  

^a Dorothea Dix Hospital   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZATROPINE; BENZATROPINE MESILATE; CARBAMAZEPINE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DIPHENHYDRAMINE; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; HYDROXYZINE; HYDROXYZINE EMBONATE; LITHIUM CARBONATE; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRIHEXYPHENIDYL; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ACUTE PSYCHOSIS; ADULT; ARTICLE; BIPOLAR DISORDER; DEMOGRAPHY; DRUG EFFICACY; ETHNOLOGY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HOSPITAL; PRIORITY JOURNAL; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SUBSTANCE ABUSE; UNITED STATES;

EID: 30344473017     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1211     Document Type: Article

References (38)

1. Kane JM, Leucht S, Carpenter D, et al. Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry 2003;64(suppl 12):1-100
2. Milner KK, Valenstein M. A comparison of guidelines for the treatment of schizophrenia. Psychiatr Serv 2002;53:888-890
3. Lehman AF, Lieberman JA, Dixon LB, et al., American Psychiatric Association. Steering Committee on Practice Guidelines. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry 2004;161(suppl 2):1-56
4. Essock SM. Editor's introduction: antipsychotic prescribing practices. Schizophr Bull 2002;28:1-4
5. Ren XS, Kazis LE, Lee AF, et al. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J Clin Pharm Ther 2002;27:441-451
6. Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002;28:589-605
7. van Bruggen J, Tijssen J, Dingemans P, et al. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol 2003;18:341-346
8. Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 2003;169:404-411
9. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-269
10. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia. Arch Gen Psychiatry 2000;57:249-258
11. Purdon SE, Woodward N, Lindborg SR, et al. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berl) 2003;169:390-397
12. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303-314
13. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorders. Am J Psychiatry 2002;159:255-262
14. Edgell ET, Anderson SW, Johnstone BM, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18:567-579
15. Tran PV, Hamilton SH, Kuntx AJ, et al. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
16. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774
17. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
18. Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother 2004;38:313-319
19. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
20. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
21. Carlson CD, Cavazzoni PA, Berg PH, et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003;64:898-906
22. Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65:57-61
23. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64:761-766
24. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(suppl 2):109-123
25. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28(suppl 1):83-96
26. Bobes J, Rejes J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003;62:77-88
27. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363
28. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865
29. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-335
30. Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003;23:1037-1043
31. Liu CY, Chiu NY, Wu CK, et al. Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int Clin Psychopharmacol 2003;18:49-51
32. Kelly DL, Nelson MW, Love RC, et al. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv 2001;52:676-678
33. Taylor DM, Wright T, Libretto SE, for the Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 2003;64:589-597
34. Lucey JV, Libretto SE. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis. Ir J Med Sci 2003;172:195-201
35. Byerly MJ, Weber M, Brooks D, et al. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003;54:742-744
36. Ascher-Svanum H, Zhu B, Faries D, et al. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry 2004;3:11; online at http://www.general-hospital-psychiatry.com/content/3/1/11
37. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004;7:22-35
38. Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics 2003;21:683-697